Aarti Drugs Ltd witnessed a sharp 2% rise in its share price during early trade on September 5, 2025, after the company announced that its new manufacturing facility has started commercial operations. The plant went live on September 4, 2025, and marks an important step in the company’s growth strategy.
This facility, set up with an investment of around ₹220 crore, will produce Dimethylamine (DMA), Monomethylamine (MMA), Trimethylamine (TMA) and their derivatives, which fall under the specialty chemicals and intermediates category. Initially, the plant will operate at nearly one-third of its total 60 MTPD capacity, with full utilization expected over the next 12 to 18 months. Financing for the project has been managed through a mix of term loans and internal accruals.
The company has clarified that these products will first cater to domestic demand before extending to international markets as opportunities open up. At present, no overseas launch has been announced. The move is also part of Aarti Drugs’ strategy of backward integration, aimed at reducing dependency on external raw material suppliers, strengthening supply chain reliability, and improving profit margins over time.
Aarti Drugs shares were up 0.87% at ₹478.50 apiece around 9.20 am. It has jumped 5.05% this year, so far.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
